- Home
- Commercial Insight Antidiabetics in Australia Reimbursement status shapes novel classes
Commercial Insight Antidiabetics in Australia Reimbursement status shapes novel classes
This market research, not available anymore on the publisher's website, was withdrawn from our database.
To get an alternative report, you can either :
- Have a look at the list of documents hereafter
- Launch a new search below
Search ReportLinker
The Largest Collection of Market Research Reports
» 450,000 Company Profiles
» 40,000 Country Guides
From +200,000 authoritative sources
DOWNLOAD THESE REPORTS NOW!
Insulin - Australia
- $ 652
- Industry report
- by Global Research & Data Services
- May 2012
- 31 pages
This market research report offers a perspective on the actual market situation, trends and future outlook for insulin in Australia. The study provides essential market information for decision-makers including: Overall market value for insulin in Australia Overall market volume for insulin in ...
Industries: Drug and Medication | Countries: Australia
Australia Pharmaceuticals and Healthcare Industry Update Quarter 3 2011
- $ 995
- Industry report
- by Business Monitor International
- May 2012
- 100 pages
BMI View: Australia's challenging economic situation is affecting its pharmaceutical industry . The acceptance of expensive patented drugs by the three main stakeholders - payers, prescribers and patients - is being superseded by the pragmatic delivery of medical services. We expect to see the formalisation ...
Industries: Drug and Medication | Countries: Australia
Peplin Inc. (Symbol:PEIC) SWOT Analysis, Strategy, Revenues and Profits
- $ 125
- Company report
- by Global Data
- May 2012
- 31 pages
Peplin Inc. (Peplin), formerly known as Peplin Biotech Ltd., is a development-stage, specialty pharmaceutical company. The company is engaged in research, advancing and commercialization of innovative medical dermatology product candidates. It focuses on developing PEP005 (ingenol mebutate), an anti-cance ...
Industries: Drug and Medication | Countries: United States, Australia
Avexa Limited (Symbol:AVX) SWOT Analysis, Strategy, Revenues and Profits
- $ 125
- Company report
- by Global Data
- May 2012
- 35 pages
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Avexa Limited SWOT Analysis report provides you a strategic analysis ...
Industries: Drug and Medication | Countries: United States, Australia
Perrigo Company (Symbol:PRGO) SWOT Analysis, Strategy, Revenues and Profits
- $ 125
- Company report
- by Global Data
- May 2012
- 45 pages
Perrigo Company is a diversified business holding company. The company is engaged in the development and manufacture of over-the-counter, prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. It operates its business through three segments: ...
Industries: Drug and Medication | Countries: United States, China, Australia, Mexico
Biotech Holdings Ltd. (Symbol:BIOHF) SWOT Analysis, Strategy, Revenues and Profits
- $ 125
- Company report
- by Global Data
- May 2012
- 17 pages
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Biotech Holdings Ltd. SWOT Analysis report provides you a strategic ...
Industries: Drug and Medication | Countries: Mexico, Canada, United States, Australia, North America, United Kingdom, World
BioDiem Ltd (Symbol:BDM) SWOT Analysis, Strategy, Revenues and Profits
- $ 125
- Company report
- by Global Data
- May 2012
- 32 pages
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. BioDiem Ltd SWOT Analysis report provides you a strategic analysis ...
Industries: Drug and Medication | Countries: Australia
Aripiprazole - Key patent, SPC, and data exclusivity expiry (7 country coverage)
- $ 568
- Industry report
- by GenericsWeb
- May 2012
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players. This Pipeline Selecto ...
Industries: Drug and Medication | Countries: Australia, United States, United Kingdom, World, Europe, Canada
Armodafinil - Key patent, SPC, and data exclusivity expiry (7 country coverage)
- $ 568
- Industry report
- by GenericsWeb
- May 2012
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players. This Pipeline Selecto ...
Industries: Drug and Medication | Countries: Australia, United States, United Kingdom, World, Europe, Canada
Atovaquone - Key patent, SPC, and data exclusivity expiry (7 country coverage)
- $ 568
- Industry report
- by GenericsWeb
- May 2012
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players. This Pipeline Selecto ...
Industries: Drug and Medication | Countries: Australia, United States, United Kingdom, World, Europe, Canada
24/7 Customer Service
You can call our customer service 24 hours a day / 7 days a week
- 00 1 718 618 48 97
Reportlinker.com © Copyright 2012. All rights reserved
